Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease A Korean nationwide, multicenter, retrospective, observational, cohort studyopen access
- Authors
- Park, Jung Gil; Tak, Won Young; Park, Soo Young; Kweon, Young Oh; Jang, Se Young; Lee, Yu Rim; Bae, Si Hyun; Jang, Jae Young; Kim, Do Young; Lee, June Sung; Suk, Ki Tae; Kim, In Hee; Lee, Heon Ju; Chung, Woo Jin; Jang, Byoung Kuk; Suh, Jeong Ill; Heo, Jeong; Lee, Won Kee
- Issue Date
- Jun-2017
- Publisher
- Lippincott Williams & Wilkins Ltd.
- Keywords
- branched-chain amino acid; complication; liver cirrhosis; nutrition; prognosis
- Citation
- Medicine, v.96, no.24
- Journal Title
- Medicine
- Volume
- 96
- Number
- 24
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7525
- DOI
- 10.1097/MD.0000000000006580
- ISSN
- 0025-7974
1536-5964
- Abstract
- Evidence of the potential benefits of long-term oral branched-chain amino acid (BCAA) supplementation in reducing the severity of liver disease is limited. Patients who were diagnosed with liver cirrhosis with a Child-Pugh (CP) score of 8-10 were included. The BCAA group consumed BCAAs daily for at least 6 months, and the control group consumed a diet without BCAA. We analyzed the improvements based on the model for end-stage liver disease (MELD) score, CP score, incidence of cirrhosis-related complications, and event-free survival over 2 years. Among the 867 recruited patients, 307 (166 in the BCAA group and 141 in the control group) were analyzed. The BCAA group was divided into 3 subgroups, whose patients consumed 4.15g, 8.3g, or 12.45g of BCAAs daily for the analysis. There were significant differences in the CP score, albumin, and hepatic encephalopathy between the 2 groups at baseline. After matching the propensity scores, we analyzed patients in the BCAA-12.45g group (12.45g of BCAAs daily, n=41) and matched control group (n=41). The MELD score significantly improved in the BCCA-12.45g group compared to the matched control group (P=.004). The changes in the serum bilirubin level (P=.014) and CP score (P=.033) over time also differed significantly between the 2 groups. The incidence rates of cirrhosis-related complications (P=.973) and development of hepatocellular carcinoma (2 cases each) did not differ significantly between the 2 groups. Long-term oral BCAA supplementation has beneficial effects in patients with advanced liver cirrhosis. A further large-scale prospective study is needed to delineate these beneficial effects.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.